Green Journals

International Approved Journals

Journal Information

Journal Title	BREAST
Publisher	CHURCHILL LIVINGSTONE
ISSN	0960-9776
E-ISSN	1532-3080
Database	Clarivate
Domain	Health Sciences, Life Sciences, Physical Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Cost-effectiveness of abbreviated breast MRI and contrast-enhanced mammography for women with extremely dense breasts in a national breast cancer screening program: a micro-simulation study
2026-12 Vol. 90 Pages 104907
Authors: Mengmeng Li, Marcel J.W. Greuter, Keris Poelhekken et al.
DOI: 10.1016/j.breast.2026.104907

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort
2026-12 Vol. 90 Pages 104943
Authors: Thomas Grinda, Matthieu Carton, Stefania Morganti et al.
DOI: 10.1016/j.breast.2026.104943

To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission
2026-12 Vol. 90 Pages 104935
Authors: Han Yi Lee, Whee Sze Ong, Vivianne Tjan-Heijnen et al.
DOI: 10.1016/j.breast.2026.104935

Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons
2026-12 Vol. 90 Pages 104934
Authors: Jingjing Xiao, Meiling Huang, Changjiao Yan et al.
DOI: 10.1016/j.breast.2026.104934

Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial
2026-12 Vol. 90 Pages 104904
Authors: Yeon Hee Park, Rina Hui, Seock-Ah Im et al.
DOI: 10.1016/j.breast.2026.104904

Prospective assessment of incomplete ovarian suppression in breast cancer using LC-MS/MS and immunoassays for estradiol
2026-12 Vol. 90 Pages 104937
Authors: Catherine M. Kelly, Lajos Pusztai, Kathleen Bennett et al.
DOI: 10.1016/j.breast.2026.104937

Transcriptomic signatures of mind-body transformations therapy in breast cancer: Downregulation of the interferon signaling pathway
2026-12 Vol. 90 Pages 104912
Authors: Stefania Cocco, Mauro Cozzolino, Michela Piezzo et al.
DOI: 10.1016/j.breast.2026.104912

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)
2026-12 Vol. 90 Pages 104911
Authors: Christopher Bedding, Kate Absolom, Katarzyna Pogoda et al.
DOI: 10.1016/j.breast.2026.104911

Prognostic role of thymidine kinase 1 activity in hormone receptor positive metastatic breast cancer. A systematic review and meta-analysis
2026-12 Vol. 90 Pages 104914
Authors: Ilenia Migliaccio, Roberto Buonaiuto, Giulia Anichini et al.
DOI: 10.1016/j.breast.2026.104914

Subtype-specific screen-detected and interval breast cancer rates in population screening: a BreastScreen Queensland cohort study
2026-12 Vol. 90 Pages 104938
Authors: Naomi Noguchi, Nick Ormiston-Smith, Michael Luke Marinovich et al.
DOI: 10.1016/j.breast.2026.104938